Stocks making the biggest moves midday: Dick's Sporting Goods, Marvell, AMD, Kura Oncology & more
Dick's Sporting Goods (DKS) fell 27% after reporting $5.59B in sales, missing estimates. Dynatrace (DT) rose 3% on a Morgan Stanley upgrade. Shift4 Payments (FOUR) gained 4% after a Wells Fargo upgrade. Moderna (MRNA) climbed 13% following a Wolfe Research upgrade. Marvell (MRVL) jumped 5% on higher price targets. AMD (AMD) rose 5% after a Raymond James upgrade. Kura Oncology (KURA) gained 10% after CEO bought shares. Navitas Semiconductor (NVTS) rose 5% on a $232.8M deal with Claros.
How this was made
The 30-second read
Why it matters
The article aggregates multiple first‑report upgrades and price moves, offering traders several short‑term entry points.
Market read
Multiple stocks experience notable intraday moves driven by fresh upgrades, earnings guidance, and deal announcements, creating short‑term trading opportunities.
What to watch
Potential supply‑chain constraints for semis and regulatory risk for biotech trials.
Background
Midday market roundup highlighting largest price moves and fresh analyst actions.
Ticker impact
Shares plunged >27% after revenue miss; sales $5.59B vs $5.65B expected.
Further downside likely if guidance remains weak.
Revenue shortfall triggered sharp sell‑off; no mitigating news.
Dynatrace rose 3% after Morgan Stanley upgraded to overweight.
Potential incremental gain on continued demand.
Analyst upgrade provides fresh catalyst but limited magnitude.
Shift4 Payments up ~4% after Wells Fargo upgraded to overweight.
Likely modest rally if execution improves.
Analyst view change is new and price‑sensitive.
Moderna rallied 13% following Wolfe Research upgrade after positive cancer vaccine trial results.
Further upside expected on trial momentum.
Positive trial data is material and drives large move.
Marvell jumped 5% after Susquehanna and Rosenblatt raised price targets.
Potential continued rally ahead of earnings.
Multiple upgrades provide fresh catalyst.
AMD gained 5% after Raymond James upgraded to strong buy with $641 target.
Likely further gains if earnings meet expectations.
Analyst upgrade is new and price‑sensitive.
Kura Oncology rose ~10% after CEO disclosed purchase of 100,000 shares in a filing.
May sustain short‑term rally.
Insider purchase is modest relative to float.
Navitas jumped 5% after announcing $232.8M cash‑and‑stock deal with Claros.
Potential upside if integration succeeds.
Deal size is material and provides clear catalyst.
Market effects
Semiconductor upgrades lift sector; biotech upgrades boost health‑care sentiment.
U.S. equities see mixed reactions across retail, tech, and biotech.
Limited to U.S. markets; no broader macro impact.
Counterpoint
Some upgrades may be premature; earnings volatility could reverse gains.
Key entities
- CompanyDick's Sporting Goods
Retailer with revenue miss
- CompanyDynatrace
AI observability platform
- CompanyShift4 Payments
Payment processing firm
- CompanyModerna
Biotech with cancer vaccine trial
- CompanyMarvell Technology
Semiconductor producer
